Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.68 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.68 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | IKBKB | O14920 | 2/20 | 0.58 |
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | DUSP22 | Q9NRW4 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195134 | 1.00 | PTPN12 (0.68) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6790878 | 0.95 | PTPN12 (0.70) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL7164248 | 0.95 | PTPN12 (0.70) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6785177 | 0.86 | PTPN12 (0.76) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6790545 | 0.85 | PTPN12 (0.77) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL46216 | 0.85 | PTPN12 (0.77) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6742617 | 0.85 | PTPN12 (0.77) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6784443 | 0.84 | PTPN12 (0.76) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL6790996 | 0.84 | PTPN12 (0.76) | PTPN12PTPN22STAT3IKBKBMAP3K5 | |
| SCHEMBL7642310 | 0.84 | PTPN12 (0.76) | PTPN12PTPN22STAT3IKBKBMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | claimed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | claimed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | claimed |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2002-05-02 | — | — | US | claimed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | claimed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | disclosed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | PTPN12 3716/4885PTPN22 3567/4885STAT3 3208/4885 |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | PTPN12 3716/4885PTPN22 3567/4885STAT3 3208/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | PTPN12 3716/4885PTPN22 3567/4885STAT3 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.